Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period.
Weeke P, Andersson C, Fosbøl EL, Brendorp B, Køber L, Sharma AM, Finer N, James PT, Caterson ID, Rode RA, Torp-Pedersen C. Weeke P, et al. Among authors: brendorp b. BMC Endocr Disord. 2010 Feb 26;10:3. doi: 10.1186/1472-6823-10-3. BMC Endocr Disord. 2010. PMID: 20184783 Free PMC article.
Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial.
Andersson C, Weeke P, Fosbøl EL, Brendorp B, Køber L, Coutinho W, Sharma AM, Van Gaal L, Finer N, James WP, Caterson ID, Rode RA, Torp-Pedersen C; SCOUT Executive Steering Committee; SCOUT investigators. Andersson C, et al. Among authors: brendorp b. Metabolism. 2009 Aug;58(8):1109-15. doi: 10.1016/j.metabol.2009.04.003. Epub 2009 Jun 18. Metabolism. 2009. PMID: 19454355 Clinical Trial.
Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial.
Andersson C, Weeke P, Brendorp B, Køber L, Fosbøl EL, Sharma AM, Finer N, Caterson ID, Rode RA, James PT, Torp-Pedersen C. Andersson C, et al. Among authors: brendorp b. Nutr Metab (Lond). 2009 Oct 14;6:42. doi: 10.1186/1743-7075-6-42. Nutr Metab (Lond). 2009. PMID: 19828038 Free PMC article.
Differential prognostic importance of QRS duration in heart failure and acute myocardial infarction associated with left ventricular dysfunction.
Fosbøl EL, Seibaek M, Brendorp B, Møller DV, Ersbøll M, Torp-Pedersen C, Køber L; Danish Investigations and Arrhythmia ON Dofetilide (DIAMOND) study group. Fosbøl EL, et al. Among authors: brendorp b. Eur J Heart Fail. 2007 Aug;9(8):814-9. doi: 10.1016/j.ejheart.2007.04.005. Epub 2007 Jun 14. Eur J Heart Fail. 2007. PMID: 17572147 Free article. Clinical Trial.
Prognostic importance of change in QRS duration over time associated with left ventricular dysfunction in patients with congestive heart failure: the DIAMOND study.
Fosbøl EL, Seibaek M, Brendorp B, Torp-Pedersen C, Køber L; Danish Investigations and Arrhythmia on Dofetilide (Diamond) Study Group. Fosbøl EL, et al. Among authors: brendorp b. J Card Fail. 2008 Dec;14(10):850-5. doi: 10.1016/j.cardfail.2008.07.238. Epub 2008 Sep 6. J Card Fail. 2008. PMID: 19041049 Clinical Trial.
Long-term prognostic importance of resting heart rate in patients with left ventricular dysfunction in connection with either heart failure or myocardial infarction: the DIAMOND study.
Fosbøl EL, Seibaek M, Brendorp B, Moller DV, Thune JJ, Gislason GH, Torp-Pedersen C, Køber L; Danish Investigations and Arrhythmia ON Dofetilide Study Group. Fosbøl EL, et al. Among authors: brendorp b. Int J Cardiol. 2010 Apr 30;140(3):279-86. doi: 10.1016/j.ijcard.2008.11.084. Epub 2008 Dec 18. Int J Cardiol. 2010. PMID: 19095316
31 results